The FDA granted full approval to pembrolizumab (Keytruda, Merck), an anti–PD-1 (programmed death-1) therapy, for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors who have progressed following prior treatment and have no satisfactory alternative treatment options.
The conversion from an accelerated to a full approval is based on results from the phase 2
APRIL 3, 2023